MedTrace Logo

The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

NCT04923295 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-14

No results posted yet for this study

Summary

Patients with average or high average peritoneal glucose transport status be included in the study as mentioned in the inclusion and exclusion criteria.

The change in peritoneal glucose transport will be evaluated before and after one month treatment with 10 mg of Dapagliflozin.

Peritoneal Equilibration Test (PET) test for patients before and after Dapagliflozin use and volume status of patients as measured by ultrafiltration from peritoneal dialysis exchanges.

The aim of the trial is to determine whether dapagliflozin can decrease glucose absorption from peritoneal fluid and reduce plasma glucose absorption from the PD fluid and thus improve ultrafiltration with a reduction in intraperitoneal glucose exposure

Conditions

  • Peritoneal Dialysis Complication
  • Ultrafiltration Failure

Interventions

DRUG

Dapagliflozin 10Mg Tab

Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients

Sponsors & Collaborators

  • An-Najah National University

    lead OTHER

Principal Investigators

  • Zakaria I Hamdan, MD · An Najah National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2021-07-28
Completion
2021-07-28

Countries

  • Palestinian Territories

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923295 on ClinicalTrials.gov